Extracellular vesicles as novel biomarkers and pharmaceutic targets of diseases

Authors: Yanfang CHEN1, Yaoliang Tang2, Guo-Chang FANG3, Dayue Darrel DUAN4
1 Department of Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, Dayton, OH 45435, USA
2 Department of Medicine,Vascular Biology Center, Medical College of Georgia, Augusta University, Augusta, GA 30912, USA
3 Department of Pharmacology and Cell Biophysics, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA
4 Department of Pharmacology, University of Nevada School of Medicine, Reno, NV 89557, USA
Corresponding to: Yanfang CHEN: yanfang.chen@wright.edu,
DOI: doi: 10.1038/aps.2018.15


Extracellular microvesicles (MVs) and exosomes (EXs) are the major types of extracellular vesicles (EVs) which can carry and transfer molecular messages (proteins, mRNAs and microRNAs, etc)[1]. Thereby, EVs could serve to mark the changes of the producing cells and to function on the recipient cells[2]. These features deem EVs as potential biomarkers and pharmacological targets for various diseases including metabolic, vascular and neurological diseases and tumors[3]. The current special feature provides reviews and original research articles on novel pharmacological studies of MVs and EXs.